Anti-Papillomavirus Antibody, 16, 18 E6 protein, clone C1P5

16.5-18 kDa

Human papilloma viruses (HPVs) can be classified as either high risk or low risk according to their association with cancer. HPV16 and HPV18 are the most common of the high risk group while HPV6 and HPV11 are among the low risk types. Approximately 90% of cervical cancers contain HPV DNA of the high risk types. Mutational analysis have shown that the E6 and E7 genes of the high risk HPVs are necessary and sufficient for HPV transforming function. The specific interactions of the E6 and E7 proteins with p53 and pRB, respectively, correlate with HPV high and low risk classifications. The high risk HPV E7 proteins bind to pRB with a higher affinity than do the low risk HPV proteins, and only the high risk HPV E6 proteins form detectable complexes with p53 in vitro.

C1P5 was made against HPV type 18 E6 protein produced in bacteria.

Epitope: 16, 18 E6 protein

Detect Papillomavirus using this Anti-Papillomavirus Antibody, 16, 18 E6 protein, clone C1P5 validated for use in IH & WB.

Immunoblotting: Reactive with a 16.5-18 kDa band in reduced westerns of overexpressing cells lines corresponding to HPV E6 protein in cells derived from human cervical carcinoma. {Banks, et al 1987}

Immunohistochemistry: Shows reactivity on formalin fixed tissue. Dilute with buffer pH 7.5-8.0 to desired working volumes. For extensive dilution, protein containing or other stabilizing medium should be used.

Immunopreciptiation: Immunoprecipiates 16.5 kDa band from human cervical carcinoma extracts {Banks, et al, 1987}.

Final working dilutions must be determined by end user.

Research Category
Infectious Diseases

Research Sub Category
Infectious Diseases - Viral

Recognizes Human papilloma virus type 18 early E6 protein. The antibody cross reacts with E6 protein from HPV type 16.

Format: Purified

Protein A Purified mouse immunoglobulin in 20 mM sodium phosphate, 250 mM NaCl, pH. 7.6, with 0.1% sodium azide as a preservative.

Protein A purified

Maintain for 1 year at 2–8°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Control
Human cervical carcinoma extract

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.